SEOUL, South Korea, June 29, 2018 /PRNewswire/ — Eone-Diagnomics Genome Center (EDGC; Co-CEO, Minseob Lee, Shangcheol Shin), the global leading company in genomic analysis, has successfully completed the ceremony celebrating its listing on the Korea Securities Dealer Automated Quotation (KOSDAQ) at the Korea Exchange on June 26.
EDGC has successfully completed the ceremony celebrating its listing on KOSDAQ at the Korea Exchange on June 26.
EDGC is the international joint venture between Eone Life Science Institute in South Korea and Diagnomics in the Unites States of America. EDGC was established in 2013. It analyzes personal genes based on big-data technology, predicts genetic diseases and suggests personalized lifestyles to prevent diseases.
EDGC mainly provides clinical and consumer genetic services based on Next Generation Sequencing (NGS) technology: the first integrated genotype and phenotype test ‘MYGENPLAN™’, personalized medical check-up ‘gene2me®Plus’, inherited ophthalmologic genetic screening test ‘MyEyeGene®‘, non-invasive prenatal test ‘NICE®‘, newborn genetic screening test ‘bebegene®‘ and so on. In addition, it has focused to enhance its competitiveness through the business expansion into the area of liquid biopsy, transplant rejection.
EDGC is striving to develop and dominate overseas markets including the Chinese market. It plans to accelerate and make headway in the market by providing genomic analysis services and transferring technologies to overseas companies. Current services available inSoutheast Asia and Middle East haveprovided excellent business results. To target overseas markets, it has acquired domestic and international certifications including, College of American Pathologists (CAP), Clinical Laboratory Improvement Amendments (CLIA), CommunauteEuropeen (CE), International Organization for Standardization (ISO) 13485.
The business value of EDGC is estimated at KRW 400 billion. The largest shareholders of EDGC are Cheol Ok Lee, Chairman of Eone Life Science Institute, largest commercial laboratory in South Korea; Kolmar Korea Holdings which is the global No. 1 in cosmetics Original Design Manufacturing (ODM); and Jun Il Kim, Founder of Lock & Lock. EDGC has attracted attention from the public priorto its listing due to the strong business results.
Shang Cheol Shin, co-CEO of EDGC, said listing on the KOSDAQ is the result of efforts by numerous people, and he added EDGC will help all the people improve their health and welfare and finally become the company which proposes the change of paradigm.
HANGZHOU, China, June 30, 2018 /PRNewswire/ — China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) (“Jo-Jo Drugstores” or the “Company”), a leading online and offline retailer and wholesale distributor of pharmaceutical and other healthcare products and a healthcare provider in China, today announced its financial results for the fiscal year ended March 31, 2018.
Mr. Lei Liu, Chief Executive Officer and Chairman of Jo-Jo Drugstores, Inc., commented, “Fiscal year 2018 has been an important transition year for China Jo-Jo Drugstores with revenues increased by 17.9% year-over-year to $96.11 million. We expanded our retail business, opening 55 new retail drugstores in key locations, and continued to improve services in our existing stores. While our e-commerce business continued its transition following the suspension of OTC drug sales on e-commerce platforms in fiscal year 2017, in the third and fourth quarters of fiscal 2018, our online pharmacy results began to stabilize as we optimized our product range.”
Mr. Liu continued, “We expect our efforts to focus on product selection and price negotiation with suppliers to increase our sales profit margin. Our e-commerce segment will continue its evolution following our initiatives to cooperate with commercial insurance companies, such as the People’s Insurance Company of China, and other active strategies. We look forward to executing our business objectives and we believe that there is still plenty of room for us to continue to grow at a rapid rate in the foreseeable future.”
Fiscal Year 2018 Financial Highlights
For the Fiscal Year Ended March 31,
($ millions, except per share data)
2018
2017
Change
Revenues
96.11
81.50
17.9%
Retail drugstores
61.98
51.79
19.7%
Online pharmacy
12.13
15.39
(21.2%)
Wholesale
22.00
14.32
53.6%
Gross profit
20.13
16.63
21.0%
Gross margin
20.9%
20.4%
0.5 pp*
Loss from operations
(18.02)
(6.10)
195.5%
Net loss attributable to Jo-Jo Drugstores
(17.06)
(5.64)
202.3%
Loss per share
(0.68)
(0.28)
141.4%
*Notes: pp represents percentage points
Revenues increased by 17.9% to $96.11 million for the fiscal year ended March 31, 2018 from $81.50 million for the last fiscal year, mainly due to the increase in retail drugstores and wholesale business, partially offset by the decrease in online pharmacy business.
Gross profit increased by 21.0% to $20.13 million for the fiscal year ended March 31, 2018 from $16.63 million for the last fiscal year. Gross margin increased by 0.5 percentage points to 20.9% from 20.4% for the last fiscal year.
Fiscal Year ended March 31, 2018 Financial Results
Revenue
Revenue for the fiscal year ended March 31, 2018 increased by $14.61 million, or 17.9%, to $96.11 million from $81.50 million for the last fiscal year. The increase in revenue was primarily due to the increase in retail drugstores and wholesale business, partially offset by the decrease in online pharmacy business.
For the Fiscal Year Ended March 31,
2018
2017
($ millions)
Revenues
Cost of Goods
Gross Margin
Revenues
Cost of Goods
Gross Margin
Retail drugstores
61.98
45.92
25.9%
51.79
38.09
26.5%
Online pharmacy
12.13
10.86
10.5%
15.39
13.83
10.1%
Wholesale
22.00
19.21
12.7%
14.32
12.95
9.6%
Total
96.11
75.99
20.9%
81.50
64.87
20.4%
Revenue from the retail drugstores segment increased by $10.19 million, or 19.7%, to $61.98 million for the fiscal year ended March 31, 2018 from $51.79 million for the last fiscal year. The increase was primarily due to the increased number of stores, close monitoring of health products suitable to communities, brand-name health product sales campaign in cooperation with brand name suppliers, and value-added customer services such as chronic disease monitoring.
Revenue from the online pharmacy segment decreased by $3.26 million, or 21.2%, to $12.13 million for the fiscal year ended March 31, 2018 from $15.39 million for the last fiscal year. The decrease was mainly caused by a decline in our sales via e-commerce platforms. The decline in sales was due to the suspension of OTC drug sales on e-commerce platforms in the second quarter of fiscal year 2017 by the CFDA. The Company is adding more non-medical health products such as nutritional supplements into our sales menu to counteract the decline in sales of OTC drug category via e-commerce platforms.
Revenue from the wholesale segment increased by $7.68 million, or 53.6%, to $22.00 million for the fiscal year ended March 31, 2018 from $14.32 million for the last fiscal year. The increase was primarily a result of the Company’s ability to resell certain products, which our retail stores made large orders on, to other vendors at competitive prices.
Gross profit and gross margin
Total cost of goods sold increased by $11.12 million, or 17.1%, to $75.99 million for the fiscal year ended March 31, 2018 from $64.87 million for the last fiscal year. Gross profit increased by $3.50 million, or 21.0%, to $20.13 million for the fiscal year ended March 31, 2018 from $16.63 million for the last fiscal year. Overall gross margin increased by 0.5 percentage points to 20.9% for the fiscal year ended March 31, 2018, compared to 20.4% for the last fiscal year.
Gross margins for retail drugstores, online pharmacy and wholesale were 25.9%, 10.5%, and 12.7%, respectively, for the fiscal year ended March 31, 2018. This compared to gross margins for retail drugstores, online pharmacy and wholesale of 26.5%, 10.1%, and 9.6%, respectively, for the last fiscal year.
Loss from operations
Sales and marketing expenses increased by $5.82 million, or 45.0%, to $18.74 million for the fiscal year ended March 31, 2018 from $12.92 million for the last fiscal year, primarily due to increase in labor and rent related to our store expansions and rising local living cost.
General and administrative expenses increased by $10.14 million, or 131.9%, to $17.82 million for the fiscal year ended March 31, 2018 from $7.68 million for the last fiscal year. The increase in general and administrative expenses was primarily due to the increased number of administrative staff and their compensation, as well as additional accounts receivable and advances to vendors allowance of $4.7 million in the fiscal year ended March 31, 2018 as compared to an increase of $0.7 million in allowance in the year ended March 31, 2017.
Impairment of long-lived assets was $1.58 million for the fiscal year ended March 31, 2018, compared to $2.12 million for the last fiscal year. Jiuxin Medicine started outsourcing its logistics service to Astro Boy Cloud Pan (Hangzhou) Storage and Logistics Co. Ltd, Jiuxin Medicine’s warehouse lease has been terminated. As a result, approximately unamortized $1,583,186 warehouse improvement is recognized as expense in the year ended March 31, 2018. Such impairment was made after we estimated that the implied fair value of long-lived assets was lower than the carrying value.
Loss from operations increased by $11.92 million, or 195.5%, to $18.02 million for the fiscal year ended March 31, 2018 from $6.10 million for the last fiscal year. Operating margin was negative 18.8% for the fiscal year ended March 31, 2018, compared to negative 7.5% for the last fiscal year.
Net loss
Net loss attributable to common shareholders for the fiscal year ended March 31, 2018 was $17.06 million, or $0.68 per basic and diluted share. This compared to net loss attributable to common shareholders of $5.64 million, $0.28 per basic and diluted share, for the last fiscal year.
Financial Condition
As of March 31, 2018, the Company had cash of $15.13 million, compared to $18.36 million as of March 31, 2017. Net cash used in operating activities was $2.07 million for the fiscal year ended March 31, 2018, compared to net cash provided by operating cash flow of $1.56 million for the last fiscal year. Net cash used in investing activities was $2.98 million for the fiscal year ended March 31, 2018, compared to $0.05 million for the last fiscal year. Net cash used in financing activities was $0.77 million for the fiscal year ended March 31, 2018, compared to net cash provided by financing activities of $10.64 million for the last fiscal year.
About China Jo-Jo Drugstores, Inc.
China Jo-Jo Drugstores, Inc. (“Jo-Jo Drugstores” or the “Company”), is a leading online and offline retailer and wholesale distributor of pharmaceutical and other healthcare products in China. Jo-Jo Drugstores currently operates retail drugstores and an online pharmacy. It is also a wholesale distributor of products similar to those carried in its pharmacies and it cultivates and sells herbs used for traditional Chinese medicine. For more information about the Company, please visit http://www.chinajojodrugstores.com/. The Company routinely posts important information on its website.
Forward-Looking Statements
This press release contains information about the Company’s view of its future expectations, plans and prospects that constitute forward-looking statements. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets into its portfolio of products and services, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the technical skills and experience necessary to meet the requirements of its clients, and its ability to protect its intellectual property. The Company’s encourages you to review other factors that may affect its future results in the Company’s annual reports and in its other filings with the Securities and Exchange Commission.
Trade accounts receivable, net of allowance for doubtful accounts of $4,561,314 and $1,415,505, as of March 31, 2018 and 2017 respectively
8,322,393
8,561,596
Inventories
13,429,568
9,923,101
Other receivables, net of allowance for doubtful accounts of $ 184,720 and $26,854, as of March 31, 2018 and 2017, respectively
3,098,079
2,269,193
Advances to suppliers, net of allowance for doubtful accounts of $3,058,092 and $1,502,255, as of March 31, 2018 and 2017, respectively
3,447,452
5,504,141
Other current assets
2,116,237
1,566,155
Total current assets
62,320,142
55,960,458
PROPERTY AND EQUIPMENT, net
2,843,640
4,263,157
OTHER ASSETS
Long-term investment
40,890
46,152
Farmland assets
796,286
718,787
Long term deposits
2,501,968
2,294,848
Other noncurrent assets
1,253,352
1,177,005
Intangible assets, net
4,056,414
2,712,611
Total other assets
8,648,910
6,949,403
Total assets
$
73,812,692
$
67,173,018
LIABILITIES AND STOCK HOLDERS’ EQUITY
CURRENT LIABILITIES
Short-term loan payable
$
–
$
–
Accounts payable, trade
25,259,526
19,441,195
Notes payable
19,180,200
12,691,575
Other payables
4,272,523
2,916,283
Other payables – related parties
850,342
927,052
Customer deposits
4,040,867
2,675,030
Taxes payable
366,040
681,939
Accrued liabilities
841,993
679,350
Total current liabilities
54,811,491
40,012,424
Purchase option and warrants liability
138,796
496,217
Total liabilities
54,950,287
40,508,641
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS’ EQUITY
Common stock; $0.001 par value; 250,000,000 shares authorized; 28,936,778 and 25,214,678 shares issued and outstanding as of March 31, 2018 and March 31, 2017
28,937
25,215
Preferred stock; $0.001 par value; 10,000,000 shares authorized; nil issued and outstanding as of March 31, 2018 and March 31,2017
–
–
Additional paid-in capital
43,599,089
36,581,248
Statutory reserves
1,309,109
1,309,109
Accumulated deficit
(29,661,190)
(12,601,257)
Accumulated other comprehensive income
3,586,460
1,350,062
Total stockholders’ equity
18,862,405
26,664,377
Total liabilities and stockholders’ equity
$
73,812,692
$
67,173,018
CHINA JO-JO DRUGSTORES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
For the years ended March 31,
2018
2017
REVENUES, NET
$
96,112,706
$
81,499,045
COST OF GOODS SOLD
75,987,537
64,872,127
GROSS PROFIT
20,125,169
16,626,918
SELLING EXPENSES
18,739,492
12,923,192
GENERAL AND ADMINISTRATIVE EXPENSES
17,823,661
7,684,862
IMPAIRMENT OF LONG-LIVED ASSETS
1,583,186
2,117,042
TOTAL OPERATING EXPENSES
38,146,339
22,725,096
LOSS FROM OPERATIONS
(18,021,170)
(6,098,178)
INTEREST INCOME
478,976
379,790
INTEREST EXPENSE
–
(1,349)
OTHER INCOME, NET
201,096
19,888
CHANGE IN FAIR VALUE OF PURCHASE OPTION AND WARRANTS LIABILITY
357,421
140,032
LOSS BEFORE INCOME TAXES
(16,983,677)
(5,559,817)
PROVISION FOR INCOME TAXES
76,256
84,387
NET LOSS
(17,059,933)
(5,644,204)
OTHER COMPREHENSIVE LOSS
Foreign currency translation adjustments
2,236,398
(1,507,751)
COMPREHENSIVE LOSS
(14,823,535)
(7,151,955)
WEIGHTED AVERAGE NUMBER OF SHARES:
Basic
25,241,748
20,396,217
Diluted
25,241,748
20,396,217
LOSS PER SHARES:
Basic
$
(0.68)
$
(0.28)
Diluted
$
(0.68)
$
(0.28)
CHINA JO-JO DRUGSTORES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
Accumulated
Common Stock
Retained Earnings
other
Non-
Number of
Paid-in
Statutory
comprehensive
controlling
shares
Amount
capital
reserves
Unrestricted
income/(loss)
interest
Total
BALANCE, March 31, 2016.
17,735,504
$
17,736
22,088,267
1,309,109
(6,957,053)
2,857,813
–
$
19,315,872
Stock based compensation
1,690,174
1,690
2,246,960
–
–
–
–
2,248,650
Net loss
–
–
–
–
(5,644,204)
–
–
(5,644,204)
Private direct offering financing
4,840,000
4,840
10,643,160
–
–
–
–
10,648,000
Issuance of common stocks in exchange of debts
949,000
949
1,602,821
–
–
1,603,810
Foreign currency translation loss
–
–
–
–
–
(1,507,751)
(1,507,751)
BALANCE, March 31, 2017.
25,214,678
$
25,215
36,581,248
1,309,109
(12,601,257)
1,350,062
–
$
26,664,377
Stock based compensation
3,722,100
3,722
7,017,841
–
–
–
7,021,563
Net loss
–
–
(17,059,933)
–
–
(17,059,933)
Foreign currency translation loss
–
–
–
–
2,236,398
–
2,236,398
BALANCE, March 31, 2018.
28,936,778
28,937
43,599,089
1,309,109
(29,661,190)
3,586,460
–
18,862,405
CHINA JO-JO DRUGSTORES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
For the years ended March 31,
2018
2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income
$
(17,059,933)
$
(5,644,204)
Adjustments to reconcile net income to net cash provided by operating activities:
Bad debt direct write-off and provision
4,009,636
679,271
Depreciation and amortization
1,383,810
1,316,747
Impairment of prepayment of lease use right
–
1,246,788
Farmland assets impairment
–
761,403
Impairment of land and road improvement
–
108,851
Impairment of leasehold improvement
1,583,186
–
Stock based compensation
7,021,563
2,248,650
Change in fair value of purchase option derivative liability
(357,421)
(140,084)
Change in operating assets:
Accounts receivable, trade
(2,072,486)
(717,386)
Notes receivable
(1,005)
(244,713)
Inventories and biological assets
(2,411,209)
191,564
Other receivables
(489,334)
(773,359)
Advances to suppliers
1,121,006
(3,020,156)
Long term deposit
15,103
–
Other current assets
(377,391)
(148,983)
Other noncurrent assets
36,091
35,509
Change in operating liabilities:
Accounts payable, trade
3,726,625
3,936,178
Other payables and accrued liabilities
1,115,267
1,250,755
Customer deposits
1,048,939
237,891
Taxes payable
(362,513)
234,780
Net cash provided by operating activities
(2,070,066)
1,559,502
CASH FLOWS FROM INVESTING ACTIVITIES:
Disposal of financial assets available for sale
–
445,968
Purchase of financial assets available for sale
(75,513)
(89,194)
Acquisition of equipment
(414,398)
(140,209)
Increase intangible assets
(1,140,102)
–
Termination of a joint venture
–
104,059
Investment in a joint venture
–
(96,180)
Additions to leasehold improvements
(1,347,489)
(270,990)
Net cash provided by (used in) investing activities
(2,977,502)
(46,546)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of short-term bank loan
–
(29,731)
Change in restricted cash
(5,664,224)
3,519,030
Proceeds from notes payable
27,461,423
24,577,096
Repayment of notes payable
(22,476,740)
(28,445,215)
Changes in other payables-related parties
–
375,659
Proceeds from sale of stock and warrants
–
10,648,000
Repayment of other payables-related parties
(91,395)
–
Net cash provided by (used in) financing activities
MVR Pro Series Offers Complete Package of Features Including 4K Ultra HD, 3D, a Built-In Touch Screen and DICOM Options
PLYMOUTH MEETING, Pennsylvania, June 28, 2018 /PRNewswire/ — MediCapture®, a global provider of medical video recorders, announced that its new MVR Pro HD medical video recorder is now commercially available with first shipments beginning in the 3rd quarter. This new state-of-the-art recorder is part of a series of advanced recorders that will launch throughout 2018, offering hospitals and surgery centers unique features that will elevate how surgical procedures are recorded and stored for post review.
(PRNewsFoto/MediCapture, Inc.)
As with all recorders in the MVR Pro Series, the MVR Pro HD comes with a handy built-in touch screen featuring intuitive icons. The icons also display when connected to external touch-screen monitors, making the recorder both versatile and easy to use.
The advanced network connectivity, including WiFi and Bluetooth, makes it easy to access and retrieve patient information and to transfer and store video files.
A DICOM option will be available soon, and a 4K Ultra HD alternative will follow.
“This represents a major step forward in medical video technology,” said Mike Bishop, CEO of MediCapture. “Never before has there been a series of medical recorders that incorporates all the latest technological advancements, yet still has the flexibility and scalability to address the visualization needs of today’s modern operating rooms, all while maintaining the ease of use for which MediCapture products are known.”
Bishop said that each recorder in the series is powered by the exclusive iMave® Pro Platform, an Integrated Medical Archiving Video Engine for next-generation OEM camera systems and medical devices.
Other MVR Pro recorders with 4K Ultra HD and DICOM will be launching throughout the year.
Demonstrations of products are available by calling 1-888-922-7887.
About MediCapture MediCapture, Inc. is the industry leader in the design and manufacture of medical video recording solutions. MediCapture’s easy-to-use recorders save high definition video and images directly to a USB flash drive, local hard drive, or network drive. The recorders work with virtually any medical video device including endoscopes, arthroscopes, surgical microscopes, ultrasounds, C-arms, and more. MediCapture also offers medical video recording solutions to OEMs and integrators. For additional information, call (888) 922-7887, or visit medicapture.com; LinkedIn.com/medicapture.
SSRN, Elsevier’s world leading preprint server and early stage research platform, has today announced the launch of ‘Preprints with The Lancet‘ – a new preprint series for sharing early stage health and medical research.
The collaboration brings together SSRN with The Lancet as part of a six-month pilot to assess whether the health and medical community are ready for this form of early research sharing.
Preprints are research papers that are at the submission stage or can be described as on-going research. By sharing online, authors widen the opportunity for receiving comments on their work by other researchers with the goal of an improved final peer-reviewed publication and for exchange of research areas with the future potential for collaboration. Preprints are primarily intended for research use; they have not been through the important steps of peer review and experienced editorial scrutiny and guidance that is part of the publishing process. All papers on ‘Preprints with The Lancet‘ will be free to upload and download.
Dr. Richard Horton, Editor-In-Chief of The Lancet, said: “Preprints have a long history in physics, mathematics, and, more recently, social sciences and biological fields, but medicine and health have been lagging behind. Our preprint pilot will be a first attempt to establish whether there is an appetite in the medical research community for obtaining feedback on ongoing or submitted research in the form of preprints, and whether such postings are a useful step in the research and publishing process.”
Authors of all research papers submitted to any Lancet family journal, will be asked at submission whether they would like their paper to be posted – as a preprint, an opt-in that all co-authors must agree to. Authors can also submit their papers through SSRN directly.
Submitted papers will be subject to SSRN’s usual checks to ensure that the paper is part of the scholarly discourse, in a subject area covered by one or more of SSRN’s networks. A Lancet editor will then check the paper and ensure the authors have provided a statement about the funding of the study; a summarized declaration of interests for all authors; a statement on ethics approval or why the research was exempted; and if the research is a randomized trial, confirmation that it has been prospectively registered along with the trial registration number. Once a final version of a preprint paper is peer-reviewed and published and becomes part of the scientific evidence as the version of record, authors are encouraged to link to the preprint of the published paper.
Gregg Gordon, Managing Director of SSRN, added: “It’s fantastic The Lancet has decided to embrace preprints and launch this new series. We have over 20 years’ experience helping researchers from across the world, and from all scientific disciplines, collaborate and share their early stage research. With the new Sneak Peek series from Cell Press recently launched on SSRN, we have two of the world’s leading journals from Elsevier working in partnership with us.”
Note for editors
Interviews with Gregg Gordon, Managing Director of SSRN, are available on request.
SSRN is a worldwide collaborative of over 350,000 authors and more than 2.2 million users that is devoted to the rapid worldwide dissemination of research. Founded in 1994, it is now composed of a number of specialized research networks. Each of SSRN’s networks encourages the early distribution of research results by reviewing and distributing submitted abstracts and full text papers from scholars around the world. SSRN encourages readers to communicate directly with other subscribers and authors concerning their own and other’s research. Through email abstract eJournals, SSRN currently reaches over 400,000 people in approximately 140 different countries.
About Elsevier
Elsevier is a global information analytics business that helps institutions and professionals advance healthcare, open science and improve performance for the benefit of humanity. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support and professional education, including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 38,000 e-book titles and many iconic reference works, including Gray‘s Anatomy. Elsevier is part of RELX Group, a global provider of information and analytics for professionals and business customers across industries. http://www.elsevier.com
Media contact David Tucker, Global Communications Elsevier +44-7920-536-160 d.tucker@elsevier.com
Do you dream of having a flat stomach? We have the solution for you!
AsiaFitnessToday present to you a challenge, over 30 days, to strengthen and tone your stomach.
The Plank Challenge is fairly easy to follow, even for beginners. Begin by holding the recommended timing for each plank, each day. It is recommended to perform the plank three times a day, excluding rest days. By the end of the Challenge, you should be able to hold your plank for 4 minutes.
To improve your quest for a flatter stomach, we recommend you to include lemon juice in your daily diet.
This post was written by Lauriane Nativel, AsiaFitnessToday.com‘s intern from La Salle Saint-Charles, Reunion Island.
NEW YORK, June 27, 2018 /PRNewswire/ — It was announced on June 15 EST in a 8-K notice from SEC that China Golden Sunset Group Limited (“CGSGL”) was finally listed in the US stock market through reverse takeover of DD’s Deluxe Rod Holder, Inc. (stock code: DDLX). CGSGL thus becomes the first company listed in the US capital market in the elderly care industry and will be supported by the international capital. Extensive attention from the industry has been attracted by CGSGL’s surprising growth speed.
The successful entry into US OTC markets of GSGL acting as the first China’s concept stock of elderly care means that it will have an absolute advantage against any other competitor in the future market occupancy. Therefore, it is a strategic selection for CGSGL to exploit the international market. With the support of international capital , CGSGL is full of confidence to expand GSGL into one of the global top 500 companies in the elderly care industry in the coming future and in answer to China’s economic development trend. GSGL will be a leader in the elderly care industry in China.
Management team of GSGL at New York Times Square of USA
12- year experience and efforts
CGSGL began with operating Xiyanghong Ecological Elderly Apartments and continued its commitment to the elderly care industry for 12 years, making an indelible contribution to the industry. In order to inherit and carry forward the Chinese traditional virtues of “filial piety makes virtue possible “, it has entered into the cooperative agreements of entrusted operation with scores of domestic nursing institutions for the agedso as to improve the living quality of the aged in all aspects and offer dignified lives for the aged.
Ms.Quan Jun, chairman of the board of CGSGL, said today in interview with a reporter of ICN, ” We are mainly engaged in collective nursing of the aged, so we set up a service system combining the nursing by professional institutions, the nursing through residing abroad and the nursing by communities. The group has integrated many resources including medical rehabilitation, health maintenance, entertainment, etc. to provide high quality and professional elder care services for the aged. In the future, we will set up a close cooperative relation with the nursing institutions for the aged across the country offering them a professional service system, and exploit overseas markets. Nowadays, the group has been listed in the US, which demonstrates its keeping ahead in the elderly care industry and also contributes to our copying the past success in the world.”
Epoch-making strategy to create surprise
2018 is a milestone for CGSGL. Besides being listed in the US, the group actively cooperates with other institutions in developing the markets of the nursing by professional institutions, the nursing through residing abroad and the nursing by communities. The nursing by communities is advocated by governments; the nursing by communities provided by CGSGL is endowed with culture, spirit, family affection and health on the basis of the traditional nursing, thus being popular among the aged and attracting the attention from the whole country including governments. The nursing through residing abroad is increasingly a trend; CGSGL took a over-two-year effort to create 12 travel routes for the aged in the country. “Mutual promotion between the nursing and the undertaking (industry) ” is the strategy for the stable advance of the group all the times.
Aging of population is a challenge and also an opportunity. The aged arenota burden but the resource of the society. Active respondance to aging means removal of the negative image of the aged such as recession, degeneration and loss; the aged may contribute to the society and achieve self-worth through mutual support. The concept of “Positive Aging” defined by W.H.O will be constructed or explained by health, guarantee and participation.
Sticking to the advanced development thinking and accelerating the elderly care industry, CGSGL is committed to the elder care services. CGSGL promotes the progress of policies, standards, facilities and talents for the aged nursing industry, and endeavors to set up an aged nursing service system which is based on the home, supported by the communities and supplemented by the external institutions with the combination of the nursing and the medical care, for the purpose of further satisfying the requirements of the aged.
MENLO PARK, California and SOUTH PLAINFIELD, New Jersey, June 27, 2018 /PRNewswire/ — Pacific Biosciences of California, Inc. (NASDAQ: PACB), the leading provider of high-quality sequencing systems for genomes, transcriptomes and epigenomes, and GENEWIZ, a leading global genomics service provider, today announced that Professor Dr. Arne Nolte of the Institute for Biology and Environmental Sciences at the University of Oldenburg, Germany and Assistant Professor Dr. Fritz Sedlazeck from the Human Genome Sequencing Center at Baylor College of Medicine in Houston, have been awarded the 2018 Plant and Animal SMRT® Grant. The grant will provide Nolte and Sedlazeck access to the PacBio® Sequel® System at GENEWIZ, as well as the materials needed and bioinformatics support to conduct comparative genomics on the newly discovered European cavefish.
The fish, Cave barbatula, was discovered in 2015 by diver Joachim Kreiselmaier as he explored the deepest parts of the Danube-Aach cave system in Southern Germany. After discussing this “strange fish” with friend and ecologist Assistant Professor Dr. Jasminca Behrmann-Godel of the Limnological Institute of the University of Konstanz, Kreiselmaier brought back a live sample for analysis.
Cavefish are found in hostile subterranean environments that lack light and nutrition and have evolved to live in a world of darkness. The fish Kreiselmaier found showed typical adaptions to cave life such as a pale body coloration, much smaller eyes, and larger nares and barbels when compared to loaches from surface locations nearby. It represents the first cavefish discovery in Europe, as well as the northernmost in the world.
Nolte and Sedlazeck have joined efforts with Behrmann-Godel to further understand the evolution of the European cavefish from its ancestors in surface waters and among other cave species, and a high-quality genome assembly will allow them to investigate the genetic make-up of organisms, including all features that are essential to understand gene function. This allows for the comparison among species to infer evolutionary changes at the level of the genome. Single Molecule, Real-Time (SMRT) Sequencing on the Sequel System provides long read lengths with uniform coverage, which leads to high accuracy and contiguity, both essential to generate complete and accurate views of a genome.
According to Dr. Fritz Sedlazeck, Assistant Professor at Baylor College of Medicine: “This grant enables us to establish the genome assembly of the European cavefish and identify genetic variants from its surface-water ancestors. We are fascinated by changes in the sensory system and pale pigmentation of the fish and we will compare its genomic makeup with the Mexican cavefish which is an important model organism in developmental biology. The outcome of this study will enable us to understand the initial steps that lead to the evolution of cave animals and impact our understanding of how multiple phenotypes evolve among vertebrates.”
According to Kevin Corcoran, Senior Vice President of Market Development for Pacific Biosciences: “We are pleased once again to partner with our certified service provider GENEWIZ to bring the winners of the 2018 Plant and Animal SMRT Grant access to highly accurate, long-read sequencing that will help further their understanding of the evolution of the European cavefish.”
According to Dr. Ginger Zhou, Vice President, Global Next Generation Sequencing for GENEWIZ: “The combination of PacBio’s powerful genomics platforms and GENEWIZ’s depth of experience in genomics and next generation sequencing provides researchers like Drs. Nolte and Sedlazeck the technology and support they require to further their discoveries and understanding of the world around us.”
ABOUT GENEWIZ GENEWIZ is a global leader in genomics services that enable research scientists within pharmaceutical, biotechnology, agriculture, environmental and clean energy, academic, and government institutions to advance their discoveries. Customers rely on our unique and proprietary genomics technologies and services, backed by our specialized experts in Sanger sequencing, gene synthesis, molecular biology, next generation sequencing, bioinformatics, and GLP regulatory-compliant services.
Headquartered in South Plainfield, NJ, GENEWIZ is privately-held with a network of laboratories in Boston, MA; Washington, D.C. Metro; Research Triangle Park, NC; San Diego, CA; San Francisco, CA; and Seattle, WA. International locations include Beijing, Suzhou, Tianjin, and Guangzhou, China; Takeley, United Kingdom; and Tokyo, Japan. For more information, visit www.genewiz.com, and connect with us on LinkedIn, Twitter, Facebook, YouTube, WeChat, and Weibo.
ABOUT PACIFIC BIOSCIENCES Pacific Biosciences of California, Inc. (NASDAQ: PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) technology, Pacific Biosciences’ products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences’ technology provides high accuracy, ultra-long reads, uniform coverage, and the ability to simultaneously detect epigenetic changes. PacBio® sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at www.pacb.com.
FORWARD-LOOKING STATEMENTS All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the suitability or utility of methods or products for particular applications, future availability, uses, quality or performance of, or benefits of using, products or technologies, and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond Pacific Biosciences’ control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in Pacific Biosciences’ most recent filings with the Securities and Exchange Commission, including Pacific Biosciences’ most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.”
Pacific Biosciences undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.
LOS ANGELES, June 26, 2018 /PRNewswire/ — ANCHEER understands advanced technology heralds new technologies to be used for humanity’s progress. A developing technology is artificial intelligence (AI), one that allows computer systems to perform tasks that humans normally do. Some of which include language translation, speech recognition, visual perception, and even decision making.
AI allows a program to do something that would normally require human intelligence. It offers great advantages in a number of things. Ranging from dealing with mundane tasks to machines taking the risk in place of humans, there could be massive potential for AI if utilized properly.
Utilizing that potential, a future development using AI technology is on the works. Since last year, the use of AI in bicycles has been teased by several manufacturers. This year, ANCHEER is pushing the development of these new AI-powered bicycles. ANCHEER is launching a new product proposal aimed to produce health bikes using AI technology to help health and fitness enthusiasts.
For decades, ANCHEER has provided premium-quality products to their customers, and now they take another step forward by using artificial intelligence to power and operate their electric bikes. More than that, this particular technology will allow bikers to use their data and turn it into insights. For people who are keen about their health, the insights provided by AI-powered bikes are vital.
These insights can help them to optimize users’ routing and health. Users can use the organized data obtained by AI bikes to create a better riding plan to improve their health and fitness. ALCHEER’s proposed new product will make use of the information to make efficient use of the bikes.
In addition, the AI-powered bikes will be able to use huge amounts of data available within the city. This information is difficult to understand and organize, which AI will be able to structure to apply for a wide array of uses. One of those uses is scheme efficiency, providing users with real-time intelligence for predicting and optimizing the users’ route throughout the city.
Other than the bikes, ANCHEER is also aiming to expand the use of artificial intelligence to their skateboard brand. If product development ensues, even skateboard users can take advantage of the benefits that artificial intelligence provides.
In healthcare, users of ANCHEER’s AI skateboards and bikes can use specific algorithms built-in within the product to analyze and understand complex medical data. It will make it easier to analyze prevention or treatment techniques as well as patient outcomes. With their new product, ANCHEER strongly believes that AI will lead the future of healthcare.
About The Company:
ANCHEER is aLos Angeles-based premium distributor of first-rate health and fitness products. It has established professional relationships allowing them to provide to customers more competitive pricing for the highest-quality product compared to average distributors. Excellent customer service and premium products are what makes ANCHEER one of the leaders in the industry.
– Starpharma licenses VivaGel® BV to Mundipharma for Europe, Russia, CIS1 and the balance of Latin America to be marketed as part of the popular BETADINE® Feminine Care portfolio
– Deal terms include a financially attractive revenue share, plus an upfront fee and eligible milestones which total up to US$15.5M
– This deal brings the total eligible milestones payable to Starpharma for all Mundipharma territories up to US$24.7M, plus revenue share
– Mundipharma plans to launch VivaGel® BV in Europeas soon as practicable
SINGAPORE, June 27, 2018 /PRNewswire/ — Starpharma (ASX: SPL, OTCQX: SPHRY) and Mundipharma today announced they have signed a licence agreement for the sales and marketing rights to VivaGel® BV for 43 countries in Europe, Russia, the Commonwealth of Independent States (CIS) and the balance of countries in Latin America. This deal builds on the VivaGel® BV licence signed with Mundipharma in May 2018 for Asia, the Middle East, Africa and parts of Latin America.
Mundipharma is a leading global pharmaceutical company and owns the successful international brand – BETADINE®. It is one of the largest privately-owned pharmaceutical companies in the world employing over 8,600 people.
The European region is an important addition to the territories already under licence with Mundipharma. Europe represents a large commercial opportunity for VivaGel® BV, enabling access to more than 260 million women. Coupled with the European Union (EU) regulatory approval already in place, this licence is expected to provide a rapid timeline for product launch. Mundipharma will proceed to launch the product under its BETADINE® brand as soon as practicable with first launches targeted for early 2019.
Consistent with the previous Mundipharma deal, Starpharma will receive returns via a revenue share on VivaGel® BV sales and is also eligible to receive signing, launch and other commercial milestones. Under the European deal, eligible milestones total up to A$20.9 million (US$15.5 million), including a US$1.5 million upfront payment. The combination of territories now under licence with Mundipharma means Starpharma is eligible to receive total signing, regulatory and commercial milestones of up to US$24.7 million, in addition to receiving revenue share.
The term of this licence is 15 years and contains commercial performance obligations, including minimum annual purchases by Mundipharma. Mundipharma is responsible for marketing, promotion and sales of the product in its licensed territories. Starpharma retains ownership of the VivaGel® BV trademark and will supply Mundipharma with VivaGel® BV. Other commercial terms of the agreement remain confidential.
Commenting on the licence, Dr Jackie Fairley, CEO of Starpharma said: “We are delighted to expand our commercial relationship with Mundipharma, owners of the rapidly growing feminine care brand, BETADINE®. In particular, Europe represents a very important market for VivaGel® BV and with this licence in place, VivaGel® BV will soon be available to millions of European women who suffer from BV. We’re impressed by Mundipharma’s commitment to the feminine care category and their plans to expedite the product launch through their extensive marketing network in Europe.”
Raman Singh, Mundipharma CEO, commented: “We’re excited to be working with Starpharma in an area of significant unmet need and to be adding this highly innovative product, VivaGel® BV, to our BETADINE® feminine care range throughout additional regions, including Europe.”
The signing of this licence for Europe is the culmination of a competitive process undertaken by Starpharma involving multiple leading pharmaceutical and women’s health companies. Significant weighting was applied to commercial terms, each company’s marketing and sales capabilities, as well as their planned time to market.
Starpharma is also in advanced commercial negotiations for marketing rights to VivaGel® BV in North America and expects to announce further licensing arrangements in the near future. Starpharma lodged its New Drug Application (NDA) with the US FDA under a Fast Track designation in April 2018.
1 CIS: Commonwealth of Independent States is a political and economic confederation of nine-member states and one associate member, all of which are former Soviet Republics located in Eurasia (primarily in Central to North Asia), formed following the dissolution of the Soviet Union.
About VivaGel® BV
VivaGel® BV is a patented, water-based vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV. VivaGel® BV is a breakthrough product which specifically targets the organisms that cause BV, rapidly relieves symptoms and has a novel mechanism of action affecting biofilm. VivaGel® BV is a non-antibiotic therapy and is not absorbed into the bloodstream.
About Bacterial Vaginosis (BV)
Bacterial vaginosis is the most common cause of vaginal infection for women of childbearing age and affects around 30% of women in the US. It is a highly recurrent condition with 50‑60% of sufferers having it recurrently. BV is caused by an imbalance of naturally occurring bacterial flora (the usual bacteria found in a woman’s vagina). Current therapies for BV are inadequate and have many unpleasant side-effects, there are also no approved products in the US for recurrent BV making VivaGel® BV a first-in-class therapy supported by large, randomised clinical studies.
About Mundipharma
Mundipharma is a network of independent associated companies which are privately owned entities covering pharmaceutical markets in Asia-Pacific, Latin America, the Middle East and Africa. The headquarters for these territories is in Singapore. Mundipharma is a prime example of an organization that consistently delivers high-quality medicines while standing by the values it represents. Its mission is to alleviate the suffering of patients and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare. For more information please visit: www.mundipharma.com
About Starpharma
Starpharma Holdings Limited (ASX: SPL, OTCQX:SPHRY), located in Melbourne Australia, is an ASX 300 company and is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications.
Starpharma’s underlying technology is built around dendrimers — a type of synthetic nanoscale polymer that is highly regular in size and structure and well suited to pharmaceutical and medical uses. Starpharma has two core development programs: VivaGel® portfolio and DEP® drug delivery with the Company developing several products internally and others via commercial partnerships.
VivaGel®: Starpharma’s women’s health product – VivaGel® BV is based on SPL7013, astodrimer sodium, a proprietary dendrimer. VivaGel® BV is approved for marketing in the EU and Australia for bacterial vaginosis (BV) and a new drug application is under Fast Track review by the US FDA. Starpharma has licensed the sales and marketing of VivaGel® BV to Mundipharma for Europe, Russia, CIS, Asia, the Middle East, Africa and Latin America; and to Aspen Pharmacare for Australia and New Zealand. Starpharma also has licence agreements to market the VivaGel® condom (an antiviral condom which includes VivaGel® in the lubricant) in several regions, including Australia, Europe, Canada, China and Japan (Okamoto). The VivaGel® condom has been launched in Australia and Canada under the Lifestyles® Dual Protect™ brand.
DEP® – Dendrimer Enhanced Product®: Starpharma’s DEP® drug delivery platform has demonstrated reproducible preclinical benefits across multiple internal and partnered DEP® programs, including improved efficacy, safety and survival. Starpharma has two internal DEP® products – DEP® docetaxel and DEP® cabazitaxel – in clinical development in patients with solid tumours, and further DEP® products approaching clinical development. Starpharma’s partnered DEP® programs include a multiproduct DEP® licence with AstraZeneca, which involves the development and commercialisation of two novel oncology compounds, with potential to add more.
This document contains certain forward-looking statements, relating to Starpharma’s business, which can be identified by the use of forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set to”, “potential”, “seeking to”, “goal”, “could provide”, “intends”, “is being developed”, “could be”, “on track”, or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA’s and other authorities’ requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management’s expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.
Lemon is a popular and refreshing fruit that can be found in many recipes. Used widely in drinks and food, it is a rich source of Vitamin C as well as other health benefits that range from being an antioxidant, antiviral to immune boosting.
It can also be used as a tool for reducing weight as it increases one’s metabolic rate. The easiest way to capitalize on this is by drinking it.
Here’s our simple Lemon Juice recipe.
Ingredients
1 Lemon
Water
Thyme
Directions
Cut the lemon in half and fully squeeze its juice out. Remove seeds if necessary.
Add the juice to a carafe of water. Add a sprig of thyme and stir to mix it.
If the juice is too bitter for your taste buds, try adding honey instead of sugar.
Enjoy!
Drink a bottle of this concoction a day and you’ll be able to see its effects soon! It’s amazing!
This post was written by Lauriane Nativel, AsiaFitnessToday.com‘s intern from La Salle Saint-Charles, Reunion Island.